Personalised organs-on-chips: functional testing for precision medicine

Research output: Contribution to journalArticleAcademicpeer-review

9 Citations (Scopus)
6 Downloads (Pure)

Abstract

Organs-on-chips are microfluidic systems with controlled, dynamic microenvironments in which cultured cells exhibit functions that emulate organ-level physiology. They can in principle be ‘personalised' to reflect individual physiology, for example by including blood samples, primary human tissue, and cells derived from induced pluripotent stem cell-derived cells, as well as by tuning key physico-chemical parameters of the cell culture microenvironment based on personal health data. The personalised nature of such systems, combined with physiologically relevant read-outs, provides new opportunities for person-specific assessment of drug efficacy and safety, as well as personalised strategies for disease prevention and treatment; together, this is known as ‘precision medicine'. There are multiple reports of how to personalise organs-on-chips, with examples including airway-on-a-chip systems containing primary patient alveolar epithelial cells, vessels-on-chips with shapes based on personal biomedical imaging data and lung-on-a-chip systems that can be exposed to various regimes of cigarette smoking. In addition, multi-organ chip systems even allow the systematic and dynamic integration of more complex combinations of personalised cell culture parameters. Current personalised organs-on-chips have not yet been used for precision medicine as such. The major challenges that affect the implementation of personalised organs-on-chips in precision medicine are related to obtaining access to personal samples and corresponding health data, as well as to obtaining data on patient outcomes that can confirm the predictive value of personalised organs-on-chips. We argue here that involving all biomedical stakeholders from clinicians and patients to pharmaceutical companies will be integral to transition personalised organs-on-chips to precision medicine.

Original languageEnglish
Pages (from-to)198-205
Number of pages8
JournalLab on a chip
Volume19
Issue number2
Early online date3 Dec 2018
DOIs
Publication statusPublished - 21 Jan 2019

Fingerprint

Precision Medicine
Medicine
Physiology
Testing
Cell culture
Cell Culture Techniques
Health
Alveolar Epithelial Cells
Cellular Microenvironment
Induced Pluripotent Stem Cells
Microfluidics
Stem cells
Tobacco Products
Pharmaceutical Preparations
Drug products
Cultured Cells
Blood
Tuning
Smoking
Cells

Cite this

@article{2c8e397d495247788435aaacb8fc0f3d,
title = "Personalised organs-on-chips: functional testing for precision medicine",
abstract = "Organs-on-chips are microfluidic systems with controlled, dynamic microenvironments in which cultured cells exhibit functions that emulate organ-level physiology. They can in principle be ‘personalised' to reflect individual physiology, for example by including blood samples, primary human tissue, and cells derived from induced pluripotent stem cell-derived cells, as well as by tuning key physico-chemical parameters of the cell culture microenvironment based on personal health data. The personalised nature of such systems, combined with physiologically relevant read-outs, provides new opportunities for person-specific assessment of drug efficacy and safety, as well as personalised strategies for disease prevention and treatment; together, this is known as ‘precision medicine'. There are multiple reports of how to personalise organs-on-chips, with examples including airway-on-a-chip systems containing primary patient alveolar epithelial cells, vessels-on-chips with shapes based on personal biomedical imaging data and lung-on-a-chip systems that can be exposed to various regimes of cigarette smoking. In addition, multi-organ chip systems even allow the systematic and dynamic integration of more complex combinations of personalised cell culture parameters. Current personalised organs-on-chips have not yet been used for precision medicine as such. The major challenges that affect the implementation of personalised organs-on-chips in precision medicine are related to obtaining access to personal samples and corresponding health data, as well as to obtaining data on patient outcomes that can confirm the predictive value of personalised organs-on-chips. We argue here that involving all biomedical stakeholders from clinicians and patients to pharmaceutical companies will be integral to transition personalised organs-on-chips to precision medicine.",
author = "{Van Den Berg}, Albert and Mummery, {Christine L.} and Robert Passier and {Van der Meer}, {Andries D.}",
year = "2019",
month = "1",
day = "21",
doi = "10.1039/c8lc00827b",
language = "English",
volume = "19",
pages = "198--205",
journal = "Lab on a chip",
issn = "1473-0197",
publisher = "Royal Society of Chemistry",
number = "2",

}

Personalised organs-on-chips : functional testing for precision medicine. / Van Den Berg, Albert; Mummery, Christine L.; Passier, Robert; Van der Meer, Andries D. (Corresponding Author).

In: Lab on a chip, Vol. 19, No. 2, 21.01.2019, p. 198-205.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Personalised organs-on-chips

T2 - functional testing for precision medicine

AU - Van Den Berg, Albert

AU - Mummery, Christine L.

AU - Passier, Robert

AU - Van der Meer, Andries D.

PY - 2019/1/21

Y1 - 2019/1/21

N2 - Organs-on-chips are microfluidic systems with controlled, dynamic microenvironments in which cultured cells exhibit functions that emulate organ-level physiology. They can in principle be ‘personalised' to reflect individual physiology, for example by including blood samples, primary human tissue, and cells derived from induced pluripotent stem cell-derived cells, as well as by tuning key physico-chemical parameters of the cell culture microenvironment based on personal health data. The personalised nature of such systems, combined with physiologically relevant read-outs, provides new opportunities for person-specific assessment of drug efficacy and safety, as well as personalised strategies for disease prevention and treatment; together, this is known as ‘precision medicine'. There are multiple reports of how to personalise organs-on-chips, with examples including airway-on-a-chip systems containing primary patient alveolar epithelial cells, vessels-on-chips with shapes based on personal biomedical imaging data and lung-on-a-chip systems that can be exposed to various regimes of cigarette smoking. In addition, multi-organ chip systems even allow the systematic and dynamic integration of more complex combinations of personalised cell culture parameters. Current personalised organs-on-chips have not yet been used for precision medicine as such. The major challenges that affect the implementation of personalised organs-on-chips in precision medicine are related to obtaining access to personal samples and corresponding health data, as well as to obtaining data on patient outcomes that can confirm the predictive value of personalised organs-on-chips. We argue here that involving all biomedical stakeholders from clinicians and patients to pharmaceutical companies will be integral to transition personalised organs-on-chips to precision medicine.

AB - Organs-on-chips are microfluidic systems with controlled, dynamic microenvironments in which cultured cells exhibit functions that emulate organ-level physiology. They can in principle be ‘personalised' to reflect individual physiology, for example by including blood samples, primary human tissue, and cells derived from induced pluripotent stem cell-derived cells, as well as by tuning key physico-chemical parameters of the cell culture microenvironment based on personal health data. The personalised nature of such systems, combined with physiologically relevant read-outs, provides new opportunities for person-specific assessment of drug efficacy and safety, as well as personalised strategies for disease prevention and treatment; together, this is known as ‘precision medicine'. There are multiple reports of how to personalise organs-on-chips, with examples including airway-on-a-chip systems containing primary patient alveolar epithelial cells, vessels-on-chips with shapes based on personal biomedical imaging data and lung-on-a-chip systems that can be exposed to various regimes of cigarette smoking. In addition, multi-organ chip systems even allow the systematic and dynamic integration of more complex combinations of personalised cell culture parameters. Current personalised organs-on-chips have not yet been used for precision medicine as such. The major challenges that affect the implementation of personalised organs-on-chips in precision medicine are related to obtaining access to personal samples and corresponding health data, as well as to obtaining data on patient outcomes that can confirm the predictive value of personalised organs-on-chips. We argue here that involving all biomedical stakeholders from clinicians and patients to pharmaceutical companies will be integral to transition personalised organs-on-chips to precision medicine.

UR - http://www.scopus.com/inward/record.url?scp=85060003588&partnerID=8YFLogxK

U2 - 10.1039/c8lc00827b

DO - 10.1039/c8lc00827b

M3 - Article

VL - 19

SP - 198

EP - 205

JO - Lab on a chip

JF - Lab on a chip

SN - 1473-0197

IS - 2

ER -